SCHEMBL3285995

SCHEMBL3285995

CC(=O)c1[nH]c(C)c(C(=O)O)c1C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.76
CYP3A4 P08684 1/20 0.76
NPSR1 Q6W5P4 2/20 0.63
ALDH1A1 P00352 5/20 0.59
MAPK1 P28482 2/20 0.59
CREBBP Q92793 2/20 0.53
BRD4 O60885 1/20 0.53
BRPF1 P55201 1/20 0.53
KMT2A Q03164 2/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 1/20 0.46
THRB P10828 1/20 0.45
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8352639 0.86 CYP1A2 (1.00) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL5513393 0.86 ALDH1A1 (0.63) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL30630152 0.84 ALDH1A1 (0.61) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL1411774 0.83 CYP1A2 (0.76) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL7127347 0.81 ALDH1A1 (0.58) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
Butane SCHEMBL10872914 0.79 ALDH1A1 (0.66) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL13983006 0.77 ALDH1A1 (0.63) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL15197087 0.77 CYP1A2 (0.61) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL10138096 0.77 CYP1A2 (0.67) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1
SCHEMBL11584471 0.77 ALDH1A1 (0.52) CYP1A2CYP3A4NPSR1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1761542-B1 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS HOFFMANN LA ROCHE (CH) 2008-01-02 EP claimed
CN-101001860-A Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (CH) 2007-07-18 CN claimed
EP-1761542-A2 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-03-14 EP claimed
WO-2005121145-A2 OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-22 WO claimed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-3157938-B1 HETERO FUNCTIONAL BINDING SYSTEMS ANTEO TECH PTY LTD (AU) 2022-03-16 EP disclosed
US-10768176-B2 Hetero functional binding systems ANTEO TECHNOLOGIES PTY LTD (AU) 2020-09-08 US disclosed
US-20170115285-A1 HETERO FUNCTIONAL BINDING SYSTEMS ANTEO TECHNOLOGIES PTY LTD (AU) 2017-04-27 US disclosed
EP-3157938-A1 HETERO FUNCTIONAL BINDING SYSTEMS Anteo Technologies Pty Ltd. (AU) 2017-04-26 EP disclosed
WO-2015192183-A1 HETERO FUNCTIONAL BINDING SYSTEMS ANTEO TECHNOLOGIES PTY LTD (AU) 2015-12-23 WO disclosed
US-7714018-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2010-05-11 US disclosed
EP-1761542-B1 OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS HOFFMANN LA ROCHE (CH) 2008-01-02 EP disclosed
CN-101001860-A Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (CH) 2007-07-18 CN disclosed
US-20070117859-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2007-05-24 US disclosed
US-7164019-B2 Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC ROCHE PALO ALTO LLC (US) 2007-01-16 US disclosed
US-20060014767-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014767-A1 Heterocyclic antiviral compounds CCR5, ACKR3, CXCR1 CYP1A2 2047/4885CYP3A4 1730/4885NPSR1 251/4885
US-20070117859-A1 Heterocyclic antiviral compounds CCR5, ACKR3, CXCR1 CYP1A2 2047/4885CYP3A4 1730/4885NPSR1 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.